You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
2-HOBA for Treatment of Pulmonary Hypertension
SBC: MTI Biotech Incorporated Topic: NHLBIPROJECT SUMMARY Although the ubiquity of metabolic problems in pulmonary hypertension (PH) has been known for more than a decade, a wealth of new details on the nature of this problem presents the opportunity for intervention. A combination of experimental work in cells and animals and early trials in humans, suggests that these metabolic problems are part of the causation for PH, and that inactiv ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension
SBC: AQUALUNG THERAPEUTICS, CORP Topic: NHLBIABSTRACT Pulmonary arterial hypertension (PAH) is a fatal disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A1 R42 Fast Track STTR application focuses on eNAMPT (extra- cellular nicotinamide phosphoribosyltransferase) as a novel, highly attractive PAH target. Aqualung Therapeutics has developed a humanized eNAMPT-neutralizing mAb, ALT-10 ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity
SBC: AQUALUNG THERAPEUTICS, CORP Topic: 300ABSTRACT Inflammatory bowel disease (IBD) is a debilitating disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A0 R42 STTR application focuses on a highly novel humanized monoclonal antibody (mAb), ALT-100, to target and neutralize eNAMPT (extracellular nicotinamide phosphoribosyltransferase), a damage-associated molecular pattern protein ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A method for accurate and sensitive detection of HIV drug-resistant minority variants
SBC: Medosome Biotec, LLC Topic: NIAIDPROJECT SUMMARY / ABSTRACT Drug resistance to HIV is a major threat to achieving long-term viral suppression in HIV+ individuals. Up to 16% of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes, and incomplete viral suppression and virologic failure are often associated with drug resistance. Therefore, current DHHS guideline recommends drug r ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
STING Activators as Therapy for Cancer
SBC: STINGINN, LLC Topic: 102PROJECT SUMMARY The Immuno-oncology (IO) arena affords a new and exciting approach to stimulate the body’s own immune system to fight cancer. The generation of anti-cancer T cells is predominantly triggered by phagocytosed cancer cells stimulating innate immune signaling pathways in professional antigen presenting cells (APC’s). This signaling process is largely governed by STING (stimulator o ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Protection of donor kidneys with synchronization modulation electric field (SMEF)
SBC: WR Biotech, LLC Topic: 400The goals of this Phase II application: 1) determine the translational significance of the i-SMEF (improved Synchronization Modulation Electric Field) in a preclinical animal model using adult Yorkshire pigs with kidney autotransplantation; and 2) determine the optimal parameters of the i-SMEF in protection against ischemic injury of the donor kidneys during cold storage and improvement of the tra ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.
SBC: ARCHER PHARMACEUTICALS, INC. Topic: NIAPathological hallmarks of Alzheimerandapos;s disease (AD) include extracellular deposits of Aβ peptides, intraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammation. Most proposed AD disease modifying therapies have focused on strategies that reduce brain Aβ/amyloid or tau pathological accumulation. However, such approaches have been unsuccessful in late stage AD clin ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Vision-Based Navigation for Formation Flight onboard ISS
SBC: JAYCON SYSTEMS LLC Topic: T11The proposed Phase II supports completion of the RINGS science missions on ISS using SVGS as real-time sensor for the EMFF maneuver. During Phase I, SVGS-based navigation of RINGS was developed and tested on a 3DOF ground-based platform, and mechanical and electrical integration of RINGS with the free-flying robotic platforms on ISS (Astrobee) was designed in detail. SVGS was deployed and tested o ...
STTR Phase II 2019 National Aeronautics and Space Administration -
Metal Digital Direct Manufacturing (MDDM) for Close-Out of Combustion Chambers and Nozzle Fabrications
SBC: Keystone Synergistic Enterprises, LLC Topic: T12This NASA sponsored STTR project will investigate methods for close-out of large, liquid rocket engine, nickel or stainless steel nozzle, coolant channels utilizing robotic laser and pulsed-arc additive manufacturing (AM)methods. Structural jacket to coolant channel land area interface strength will be quantified and metallurgical characterization completed.Process optimizations will be conducted ...
STTR Phase II 2019 National Aeronautics and Space Administration -
An Automated Patient Chart Error Detection System for Radiation Therapy
SBC: Infondrian LLC Topic: 101Project Summary/Abstract Every year, approximately 1,200 severe mistreatments happen in radiation therapy. Radiation therapy lawsuits rank in the top third of all medical specialties with an average of $313,000 per claim settled or litigated. The current method for detecting treatment errors is by a weekly patient chart check, where each treatment record is manually reviewed on a weekly basis. Thi ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health